Monograph
R03AK04 - Salbutamol and Sodium Cromoglicate |
Propably not porphyrinogenic |
PNP |
Rationale
salbutamol: Rather low dose, in large parts excreted unmetabolized. No data pointing to clinical CYP-interaction. Four references consider it safe. ipratropium: Hydrophilic substance, insignificant systemic exposure.
Chemical description
salbutamol: Adrenergic beta-receptor stimulating agent used in asthma. Administered as salbutamol sulfate in micronized form in inhalation aerosol (2,5 - 5 mg/dose). No clinical data pointing to CYP-interaction. About 35% of the dose is excreted in unchanged form in urine. ipratropiumbromide Ipratropiumbromide, a quarternary ammonium compound with anticholinergic properties. used in inhalation aerosol (21-42 ug/dose) as bronchodilator in chronic obstructive pulmonary disease and in asthma. No data poiinting to CYP-interaction. salbutamol: EPI-list: safe South African list: use French list: authorized. Kauppinen and Mustajoki. Prognosis of acute porphyria... Medicine 1992; 71: 1-13: tolerated (n=2)
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom
Poland© NAPOS 2024